Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    18970976 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Condition: Multiple Sclerosis
Interventions: Drug: Rebif (IFN β-1a subcutaneous three times per week);   Drug: Tecifdera (dimethyl fumarate)
2 Completed Efficacy and Safety of BG00012 in MS
Condition: Multiple Sclerosis
Intervention: Drug: BG00012

Indicates status has not been verified in more than two years